drugset / Trial / NCT00877539

A Study To Assess The Effect Of PF-03526299 On Lung Function Following An Allergen Challenge In Asthmatic Subjects

NCT00877539

Phase 1 Completed 29 enrolled Pfizer
RandomizedCrossoverDouble-blindTreatment

Summary

PF-03526299, a novel anti-inflammatory agent should attenuate the effect of a bronchial allergen challenge on lung function and hence provide proof of mechanism for this agent.

Timeline

Start
2009-06
Primary completion
2009-12
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Fluticasone propionate Other / unclassified Inhaled
Subject PF-03526299 Unknown Inhaled

Indications